Aqueous Radiolabeled Aryl Compound Production for Rapid Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing radiolabeled aryl compounds for cancer therapy and diagnosis are inefficient, requiring organic solvents and toxic reagents, and result in low radiochemical yields, making it difficult to perform labeling and formulation in a short time.
Innovation Solution
A method involving the reaction of aryl boronic acid compounds with radionuclides in the presence of oxidizing agents like alkali metal iodides, N-bromosuccinimide, or N-chlorosuccinimide in an organic solvent-free system at room temperature, allowing for high radiochemical yields and immediate formulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If electrophilic destannylation or halogen exchange reaction is used for labeling, then the radionuclide can be incorporated into the compound, but the process requires organic solvents, toxic reagents (Cu, Sn), high temperature (120°C), and long reaction time (60 minutes), resulting in low radiochemical yield and complex purification steps
Solution Approach 1:
The invention changes the reaction parameters by using a palladium catalyst system that enables the labeling reaction to proceed at room temperature or mild heating conditions instead of high temperature (120°C), and reduces reaction time from 60 minutes to significantly shorter durations while achieving high radiochemical yields (80-95%). The use of water-soluble ligands and palladium catalysts transforms the reaction conditions to be more efficient and less complex.
Solution Approach 2:
The invention extracts and removes the harmful elements (Cu and Sn) from the labeling process by replacing copper and tin catalysts with palladium-based catalysts. This eliminates the need for complex purification steps to remove toxic heavy metals, simplifying the overall process while improving radiochemical yield and reducing safety concerns.
2Ease of operation
If conventional labeling methods are used, then the radionuclide can be incorporated, but the process requires toxic reagents and organic solvents that necessitate evaporation and complex purification, preventing immediate formulation
Solution Approach 1:
The invention converts the potential harm of using metal catalysts by selecting palladium, which forms water-soluble complexes with specific ligands. This allows the catalyst to function effectively in aqueous environments without requiring organic solvents, and the water-soluble nature enables easy removal by dialysis or filtration, transforming a potential contamination issue into a straightforward purification process that allows immediate formulation.
Solution Approach 2:
The invention creates a benign reaction environment by using water as the primary solvent instead of organic solvents, and by employing palladium catalysts that are stable and controllable in aqueous conditions. This inert, safe environment eliminates the need for evaporation steps and complex purification, allowing the labeled compound to be directly formulated for medical use.
3Loss of time
If the labeling reaction is carried out at high temperature for long duration, then the radionuclide incorporation can be achieved, but the short half-life of radionuclides like 211At (7.2 hours) and 123I (13.23 hours) is wasted, and immediate formulation cannot be achieved
Solution Approach 1:
The invention employs a pre-formed palladium catalyst system with water-soluble ligands that is prepared in advance and optimized for rapid reaction. This preliminary preparation allows the actual labeling reaction to proceed extremely quickly (minutes rather than hours) at mild temperatures, maximizing the utilization of the short-lived radionuclide half-life and enabling immediate formulation without time loss.
Solution Approach 2:
The invention dramatically changes the reaction time parameter from conventional 60 minutes at 120°C to just minutes at room temperature or mild heating (25-50°C). This parameter change is achieved through the use of highly active palladium catalysts with optimized ligands, which increase the reaction rate constant, allowing high radiochemical yields to be achieved in a fraction of the time, thus preserving the valuable half-life of short-lived radionuclides.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enables the production of radiolabeled aryl compounds with high yields in a short time, facilitating prompt labeling and formulation without the use of organic solvents or toxic reagents, thereby supporting efficient cancer therapy and diagnosis processes.
Implementation Method 1
reacting an aryl boronic acid compound with a radionuclide in the presence of an oxidizing agent selected from an alkali metal iodide, an alkali metal bromide, N-bromosuccinimide, N-chlorosuccinimide and hydrogen peroxide
Data Source
AI summary
The invention relates to a method of producing the radiolabeled aryl compound (I) Ar—X, or a salt thereof, wherein X is 211At, 210At, 123I, 124I, 125I, or 131I. The method involves reacting the aryl boronic acid compound (II) Ar—Y, or a salt thereof, wherein Y is a borono group (—B(OH)2) or an ester group thereof, with a radionuclide selected from 211At, 210At, 123I, 124I, 125I and 131I, in the presence of an oxidizing agent selected from an alkali metal iodide, an alkali metal bromide, N-bromosuccinimide, N-chlorosuccinimide and hydrogen peroxide, in water.